Dopamine Agonist Pills Shrink Prolactin Tumors in Men, but Hormones and Size Tell Different Stories

Men with prolactinomas — benign pituitary tumors that flood the bloodstream with the hormone prolactin — often arrive at the clinic late, carrying larger tumors and deeper hormonal damage than their female counterparts. A new retrospective cohort study from Huashan Hospital of Fudan University in Shanghai now offers one of the most detailed real-world pictures yet of how these men respond to the standard first-line treatment, dopamine agonist pills, and the findings carry a provocative message: the three yardsticks doctors routinely use to judge success — prolactin levels, tumor size, and testosterone recovery — frequently disagree with one another. Judging treatment by any single measure, the researchers argue, can mislabel a patient’s true trajectory.

The study, published in BMC Endocrine Disorders, followed 108 Chinese men with prolactinoma who received dopamine agonist monotherapy and were tracked for more than a year at the single tertiary center. The mean age at diagnosis was 41.8 years, with a wide spread of roughly 15 years on either side. The disease burden at baseline was striking: the median starting prolactin concentration was 1,039 nanograms per milliliter, orders of magnitude above the normal range, and the median tumor volume was about 2,710 cubic millimeters. Nearly 77 percent of the men had macroadenomas, tumors large enough to be clearly visible and potentially compress surrounding structures, while only about 23 percent had smaller microadenomas. This skew toward advanced disease reflects a well-recognized pattern in male prolactinoma, where symptoms such as reduced libido, erectile dysfunction, and headaches are often dismissed or attributed to other causes until the tumor has grown substantially.

Over a mean follow-up of 2.84 years, the treatment worked remarkably well by most conventional standards. Prolactin levels normalized in 69.4 percent of patients, tumor volume shrank by at least half in 79.6 percent, and 54.6 percent achieved both prolactin normalization and recovery of testosterone, the key hormone of the male gonadal axis. In ten patients the tumor disappeared entirely on imaging — an outcome that was far more common in men with microadenomas, where complete disappearance occurred in 28 percent of cases, compared with just 3.6 percent of macroadenomas. That difference, statistically significant at P equals 0.001, underscores how much the starting tumor size shapes what patients can ultimately expect from medication alone.

But the headline numbers conceal the study’s central insight. When the researchers integrated prolactin control and tumor shrinkage into a single combined classification, they found that discordant responses were common. At the last follow-up, 56.5 percent of the men met the criteria for a good response — normal prolactin plus at least 50 percent tumor-volume reduction — while 36.1 percent fell into a partial response category, meaning one measure improved while the other lagged. Some men normalized their prolactin yet retained bulky residual tumors; others saw dramatic shrinkage while the hormone remained stubbornly elevated. Only 7.4 percent had a poor response, with neither prolactin control nor meaningful tumor reduction. In other words, more than a third of patients would have been misclassified by a single-endpoint assessment.

To move beyond static snapshots, the team built what they call a dynamic integrated response framework, evaluating patients at baseline, at three months, and at one year, and asking which measurements at each stage best predicted the final outcome. The statistical machinery behind this included group comparisons, stage-specific logistic regression, receiver-operating-characteristic analysis to identify cutoff values, and bootstrap internal validation to test the robustness of the models. Sensitivity analyses were used to confirm that the findings were not driven by particular subgroups or analytic choices. The result is a time-stamped map of treatment response rather than a single verdict rendered at the end of follow-up.

The predictors that emerged differed sharply by stage. At baseline, the only significant independent predictor of a final good response was body mass index: lower BMI was associated with better outcomes, with an odds ratio of 0.810 per unit increase in BMI. Why body weight should matter remains an open question, but the association hints at metabolic influences on dopamine agonist sensitivity or on tumor biology itself. By three months, the picture shifted to treatment dynamics: each 10 percent greater reduction in prolactin at that early checkpoint nearly tripled the odds of a final good response, with an odds ratio of 3.093. This suggests that the first three months of therapy are a critical window in which the tumor’s behavior reveals its long-term trajectory.

At the one-year mark, two factors independently predicted a good final response. Prolactin normalization by then carried an odds ratio of 17.712 — a very strong signal — while each additional 10 percent of tumor-volume reduction added a more modest but still significant benefit, with an odds ratio of 1.106. The receiver-operating-characteristic analysis translated these associations into practical exploratory thresholds: a prolactin reduction of at least 94.8 percent at three months, and an absolute prolactin level at or below 23.30 nanograms per milliliter at one year, best separated patients destined for good responses from the rest. These cutoffs are exploratory and require external validation, but they offer clinicians concrete numbers to watch at defined moments in follow-up.

The clinical implications are potentially far-reaching. Current guidelines for managing prolactinoma largely assess treatment success through individual endpoints, and a patient whose prolactin has normalized might be considered a treatment success even if a large tumor mass persists and continues to threaten vision or pituitary function. Conversely, a patient with marked tumor shrinkage but persistently elevated prolactin might be labeled a failure despite clear radiological benefit. The integrated framework distinguishes transitional partial responses — patients still moving toward full control — from persistent ones, allowing clinicians to intensify monitoring, adjust drug doses, or consider surgery or radiotherapy at the right time rather than too late. The authors emphasize that the framework is a candidate endpoint structure for future validation studies, not a finished clinical tool.

Several caveats temper the enthusiasm. The study was retrospective and drawn from a single center, which limits generalizability and leaves open the possibility of selection effects; patients who required surgery or radiotherapy during follow-up were excluded, which may have removed the most treatment-resistant cases from the analysis. The cohort was exclusively male and exclusively Chinese, and prolactinoma behavior and drug tolerance can vary across populations. The response classification, while logically constructed, is new and has not yet been tested prospectively or in independent cohorts. Still, the size of the cohort — 108 men followed for nearly three years on average — is unusual for a disease that is rare in men, and the internal validation strengthens confidence in the identified predictors.

For patients, the takeaway is cautiously optimistic. Dopamine agonist monotherapy achieved high rates of both biochemical and structural control across all tumor sizes in this cohort, confirming that pills alone can do the heavy lifting for most men with prolactinoma, even those presenting with large tumors and prolactin levels a thousand times above normal. For clinicians, the study argues for a more nuanced follow-up rhythm: check prolactin and MRI early, watch the trajectory rather than the snapshot, and recognize that a discordant response is not a contradiction but a distinct clinical state deserving its own management strategy. As endocrinology moves toward personalized, time-dependent assessment of chronic endocrine diseases, this integrated response framework offers a template that could extend well beyond prolactinoma — provided that future prospective studies confirm what this Shanghai cohort has revealed.

Subject of Research: Dopamine agonist monotherapy outcomes in men with prolactinoma

Article Title: Dynamic integrated response to dopamine agonist monotherapy in Chinese men with prolactinoma: a retrospective cohort study

Article References: Zheng, H., Hu, B., Xie, Y., Qu, X., Zhang, S., Ye, H., Li, Y., Lu, R., & Ji, L. (2026). Dynamic integrated response to dopamine agonist monotherapy in Chinese men with prolactinoma: a retrospective cohort study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02636-w

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02636-w

Keywords: prolactinoma, dopamine agonist, prolactin, testosterone, pituitary adenoma, tumor volume, endocrinology, retrospective cohort, treatment response, BMI, macroadenoma, hormonal therapy